Recursion Pharmaceuticals $300 Million At-the-Market Offering

"Davis Polk advised the sales agent in connection with Recursion Pharmaceuticals' SEC-registered at-the-market offering of Class A common stock for up to $300 million. The stock is listed on the Nasdaq Global Select Market under the symbol RXRX. Recursion is a clinical-stage biotechnology company headquartered in Salt Lake City, Utah."

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Recursion Pharmaceuticals, Inc. The offering consisted of Recursion Pharmaceuticals' Class A common stock, offered pursuant to an at-the-market program for up to an aggregate amount of $300 million. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol RXRX. Recursion Pharmaceuticals is a clinical-stage biotechnology company focused on industrializing drug discovery by decoding biology and is headquartered in Salt Lake City, Utah. Davis Polk represented the sales agent with a team composed by: partners Alan F. Denenberg (corporate) and Beth LeBow (corporate); associates Savannah J. Dowling (corporate), Rebecca Lei (corporate) and Ashley Jaworoski (corporate); partner Frank Azzopardi (intellectual property) and associate Hannah Coleman (intellectual property); counsel Liang Zhang (tax) and associates Alanna Phillips (tax) and Fred (Chen) Fu (tax). Members of the team were based in the Northern California and New York offices.

Menu

Recursion Pharmaceuticals $300 Million At-the-Market Offering

Read the full story

Menu

Recursion Pharmaceuticals $300 Million At-the-Market Offering

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads